# Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

> **NCT06271616** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease
- Hematopoietic and Lymphatic System Neoplasm

## Interventions

- **PROCEDURE:** Echocardiography Test
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT06271616
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06271616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06271616, "Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06271616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*